Humans ; Infant, Newborn ; Male ; Radiography ; Retroperitoneal Space ; pathology ; Rhabdomyosarcoma ; diagnostic imaging ; pathology ; physiopathology

Arrhythmogenic Right Ventricular Dysplasia ; complications ; Autopsy ; Cardiomyopathy, Hypertrophic ; complications ; Cause of Death ; Coronary Disease ; complications ; Coronary Vessel Anomalies ; complications ; Death, Sudden, Cardiac ; etiology ; pathology ; Humans

Apoptosis ; Apoptosis Regulatory Proteins ; genetics ; Genetic Vectors ; Humans ; K562 Cells ; Transfection

Objective To observe the effects of self-made Yicong-Shugan drink in the treatment of anxiety disorders before the college entrance examination.Methods Random number table was adopted for dividing 121 outpatients with anxiety disorders before the college entrance examination in the People's Hospital of Gaomi and Gaomi TCM Hospital since January 2007 to March 2011 into a treatment group with 69 cases,and a control group with 52 cases.The treatment group was treated with Yicong-Shugan Decoction,while the control group was given alprazolam.Hamilton Anxiety Scale (HAMA),the Clinical Global Impression Scale (CGI) and Anxiety Rating Scale (SAS) were used to determine the clinical efficacy in both groups before treatment and 1,2,4,6 weeks after the treatment.Results ① In the control group after treatment,one week HAMA score (23.1 ±7.9) was significantly changed than before the treatment (31.1 ±7.6) (P＜0.05); whereas no significant change in the treatment group (P＜0.05).This demonstrated that alprazolam has a faster affection than Yicong-Shugan drink.② HAMA integral scores,CGI integral scores and SAS scores of both groups at 2,4,6 weeks after treatment were:HAMA integral score:(22.6 ± 7.5),(11.7 ± 5.3),(7.9 ± 5.4) in the treatment group,while (18.7 ±6.9),(13.8 ±6.7),(11.8 ±6.5) in the control group; CGI integral score:(3.4 ±0.7),(2.1 ±0.6),(1.8 ±0.7) in the treatment group,while (3.2 ±0.8),(1.8±0.5),and (1.6 ±0.6) in the control group; the SAS scores:(53.8±8.5),(38.7 ±9.6),(30.6 ±7.6) in the treatment group,while (50.2 ±8.9),(41.5 ±9.8),and (39.2 ±8.3) in the control group respectively.All these scores showed significant difference than those before the treatment in the same group (P＜0.01).HAMA and SAS scores in the treatment group were significantly lower than the control group after the treatment (P＜0.01).This demonstrated that both alprazolam tablets and Yicong-Shugan drink have a good anxiolytic effect,but Yicong-Shuxin drink has a longer lasting effects.Conclusion Self made Yicong-Shugan drink can effectively improve the patient with college entrance examination anxiety disorder.Alprazolam tablets have a quicker effects than self-made Yicong-Shugan decoction,while Yicong-Shuxin decoction has a longer lasting effects than alprazolam.

ObjectiveTo observe the effects of Shengqing-Jiangzhuo decoction combined with western medicine on metabolic syndrome.Methods120 patients with metabolic syndrome in Gaomi City People's Hospital of Traditional Chinese Medicine from March 2008 to July 2011 were randomly divided into a treatment group and a control group according to case number,with 60 cases in each group.The control group was treated with Western medicine individualized and symptomatic treatment,while on the basis of the control group the treatment group was additionally treated with Shengqing-Jiangzhuo decoction.Both groups were continuously treated for 2 months.The main symptoms of the two groups of patients before and after clinical efficacy as well as blood pressure,body mass index (BMI),waist-hip ratio (WHR) lipid levels,glycosylated hemoglobin (HbA1C) changes were observed.Results① The clinical efficacy:After treatment,dizziness,dry mouth,constipation,bloating,irritability and other symptoms improved significantly,with 85.00％ and 73.33％ of the total effective rate in treatment group and control group respectively; ② laboratory parameters detection:there was statistical difference between the control group and the treatment group in terms of systolic blood pressure (127.30±8.00) mm Hg,diastolic blood pressure (81.35±3.81) mm Hg,body mass index (23.3±1.48),waist-hip ratio (0.85 ± 0.07),as well as cholesterol (3.32 ± 0.81)mmol/L triglyceride (1.76 ±1.01) mmol/L,low-density lipoprotein cholesterol (2.20±0.72)mmol/L,high density lipoprotein cholesterol (1.39±0.14) mmol/L,glycosylated hemoglobin (6.58±0.82) mg/dl,(P＜0.05 or P＜0.01).Conclusion Shengqing-Jiangzhuo decoction significantly improved the clinical efficacy of metabolic syndrome.

Objective To observe the effect of treating chronic renal failure with self-made Huazhuo Baoyuan decoction.Methods 90 patients of chronic renal failure belonging to spleen and kidney yang deficiency and turbid toxic obstruction type diagnosed by TCM syndrome differentiation were randomly divided into a treatment group and a control group according to the date of reception.40 cases in the control group were treated with conventional western medicine,which were low-salt high-quality low-protein diet; to correct acid-base balance and electrolyte imbalance; to correct anemia; adding amino acids; to control blood sugar in patients with history of diabetes; to control blood pressure in patients with hypertension.50 patients in the treatment group were additionally treated with self-made Huazhuo Baoyuan decoction on the basis of the control group.Such indexes as symptom score,serum creatinine (Scr),blood urea nitrogen (BUN),endogenous creatinine clearance rate (Ccr),hemoglobin (Hb),liver function:aspartate aminotransferase (AST),alanine aminotransferase (ALT) ; lipids:total cholesterol(TC),triglyceride(TG),high density lipoprotein cholesterol(HDL-C),low-density lipoprotein cholesterol (LDL-C) were observed before and after the treatment.Results After treatment,total effective rate was 88.0％ and 67.5％ in the treatment group and the control group respectively,the difference was statistically significant (P=0.012).The value of Scr (292.95± 85.95) μmol/L,BUN (22.69 ± 9.84) mmol/L,Ccr (22.69 ±9.84)rn1/min,CH(6.23 ± 0.57)mmol/L,TG(1.70± 0.22)mmol/L,HDL-C(1.45 ± 0.04)mmol/L,LDL-C(3.30 ±0.60) mmol/L showed significant difference after the treatment than before in the treatment group (P＜0.05 or P＜ 0.01).Compared with the control group of after treatment [Scr (336.63 ± 90.77)μmol/L,BUN(10.47 ±2.71) mmol/L,Ccr (19.47 ± 6.71) rnl/min,CH (7.21 ± 0.62) mmol/L,TG (2.30 ± 0.27) mmol/L,HDL-C (0.87 ±0.05)mmol/L,LDL-C (5.60±0.70)mmol/L],the difference was statistically significant(P＜0.05).Conclusion Self-made Huazhuo Baoyuan decoction was effective and safe to treat chronic renal failure.

Beckwith-Wiedemann Syndrome ; Female ; Humans ; Infant, Newborn

Objective To study the method for preparing the polyamine cotton fiber loaded with Cu2+ and to test the antibacterial effect of the cotton fiber. Methods The natural cotton fiber was treated through basification, epoxygenation, alkene amination and Cu2+ adsorption. 8 kinds of microorganisms were used for the bacteriostasis test. Results The modified fibers showed a good antimicrobial effect to gram-negative bacteria and the bacteriostasis value achieved 6. The minimal sterilization concentrations of the Cu2+-diethylene triamine cotton fiber, Cu2+-triethylene tetramine cotton fiber and Cu2+-tetraethylene pentamine cotton fiber were 12 mg/ml, 14 mg/ml and 10 mg/ml respectively. The antibacterial process of the cotton fiber included two parts, adsorption and sterilization. The acting site was on the cell membrane. A positive relationship was seen between the concentration of antibacterial cotton fiber and the dissolved rate of bacteria. Conclusion The metal ion fiber shows an excellent performance of broad-spectrum antibacterial effect, especially to gram-negative bacteria and may be the "contact killing" is the acting manner of the antibacterial cotton fiber.

Objective To study the mechanism of insulin resistance in obesity, impaired glucose tolerance (IGT) and type 2 diabetes. Methods Insulin sensitivity index (SI), glucose effectiveness (S G) and insulin secretory function of ? islet cells were assessed by the reduced sample number of Bergman's minimal model method with frequently sampled intravenous glucose tolerance test in patients with obesity, IGT and type 2 diabetes as well as in the controls. Body mass index (BMI) and waist hip ratio (WHR) were determined in four groups. Results SI and S G were significantly higher in the controls than those in the IGT and type 2 diabetes patients. The S G in obesity group was nearly the same as that in the controls, but its SI was significantly lower. The area under curve 1 (AUC 1) of insulin in the controls was smaller than that in obesity and IGT (P

Objective To investigate the difference and significance of the glucocorticoid receptors of the peripheral leukocytes in patients with acute spinal cord injury or with chronic spinal cord compression. Methods Glucocorticoid receptors binding sites on the peripheral leukocytes in 20 patients with acute spinal cord injury and 21 patients with chronic spinal cord compression were measured by the radioligand binding assay. Results Glucocorticoid receptors binding sites on peripheral leukocytes from the patients with acute spinal cord injury is 2 517?857.8 per cell, the patients with chronic spinal cord compression is 4 225?1 271 per cell and outcome is 2 279?921 per cell in the patients with complete paralysis, 2 806?718 per cell in the incomplete paralysis patients. T test was used to evaluate the final outcome. Conclusion Glucocorticoid receptors binding sites on the peripheral leukocytes consist of two kinds: the high affinity binding sites and the low affinity binding sites. The high affinity glucocorticoid receptors binding sites on peripheral leukocytes in patients with acute spinal cord injury decrease and low affinity binding sites remain unchanged. Large doses of glucocorticoid combine the low affinity binding sites on peripheral leukocytes which inhibits the tendency of movement of leukocytes to the injured spinal cord; so inflammatory reaction produced by acute injury can be alleviated and thus the spinal cord was protected. There is no curative effect by using large doses of glucocorticoid to treat patients with chronic spinal cord compression.